Blood

Primary central nervous system lymphoma

ORPHA:46135 ↗

Search all Primary central nervous system lymphoma trialsAlert me when a trial opens

studies recruiting now

as of 7 Sept 2026

411

studies registered in total

as of 7 Sept 2026

countries with a recruiting site

as of 7 Sept 2026

6 Aug 2026

most recent study posted

among recruiting studies

Recruiting trials

RecruitingPhase 3NCT07104032

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Sponsor Ono Pharmaceutical Co., Ltd.Where United States, Australia, Czechia +3 (33 sites)Studying Tirabrutinib, RituximabUpdated 3 Sept 2026

See details

RecruitingPhase 2NCT07015242

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyWhere United States, France, Germany (40 sites)Studying Rituximab, MethotrexateUpdated 1 Sept 2026

See details

RecruitingPhase 2 / Phase 3NCT07185373

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Sponsor Huashan HospitalWhere China (15 sites)Studying Teniposide, OrelabrutinibUpdated 19 Aug 2026

See details

RecruitingPhase 1NCT06607549

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

Sponsor University of UtahWhere United States (3 sites)Studying Loncastuximab tesirine and rituximab (Lonca-R)Updated 10 Aug 2026

See details

RecruitingPhase 2NCT07749365

Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

Sponsor The First Affiliated Hospital of Xiamen UniversityWhere China (1 site)Studying hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamabUpdated 6 Aug 2026

See details

Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.

See all 74 recruiting studies

Where recruiting studies are running

Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.

Australia China Czechia France Germany Italy Spain United States

Keep watching

Get an email when a new Primary central nervous system lymphoma study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:46135 ↗

About Primary central nervous system lymphoma

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Orphanet expert page ↗GARD (NIH) ↗

Treatments being studied

25 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Phase 3Rituximab (Blitzima)

Phase 3Orelabrutinib (Innobruka)

Phase 3Methotrexate (Ebetrex)

Phase 3Temozolomide (Temodal)

Phase 2Nivolumab (Nivolumab bms)

Phase 2Cytarabine (Alexan)

Phase 2Filgrastim (Accofil)

Phase 2Lenalidomide (Lenalidomide accord)

+ 17 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).